Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China.
OMNI Research Group, Ottawa Hospital Research Institute, Ottawa, Canada.
Sci Rep. 2020 Jun 1;10(1):8848. doi: 10.1038/s41598-020-65051-8.
The interaction of gut microbiota, related metabolites and inflammation factors with nonalcoholic fatty liver disease (NAFLD) remains unclearly defined. The aim of this systematic review and meta-analysis was to synthesize previous study findings to better understand this interaction. Relevant research articles published not later than September, 2019 were searched in the following databases: Web of Science, PubMed, Embase, and Cochrane Library. The search strategy and inclusion criteria for this study yielded a total of 47 studies, of which only 11 were eligible for meta-analysis. The narrative analysis of these articles found that there is interplay between the key gut microbiota, related metabolites and inflammation factors, which modulate the development and progression of NAFLD. In addition, the results of meta-analysis showed that probiotic supplementation significantly decreased tumor necrosis factor-α (TNF-α) in NAFLD patients (standardized mean difference (SMD) = -0.52, confidence interval (CI): -0.86 to -0.18, and p = 0.003) and C-reactive protein (CRP) (SMD = -0.62, CI: -0.80 to -0.43, and p < 0.001). However, whether therapies can target TNF-α and CRP in order treat NAFLD still needs further investigation. Therefore, these results suggest that the interaction of the key gut microbiota, related metabolites and inflammation factors with NAFLD may provide a novel therapeutic target for the clinical and pharmacological treatment of NAFLD.
肠道微生物群、相关代谢物和炎症因子与非酒精性脂肪性肝病(NAFLD)之间的相互作用仍不清楚。本系统评价和荟萃分析的目的是综合以前的研究结果,以更好地理解这种相互作用。在以下数据库中检索了截至 2019 年 9 月发表的相关研究文章:Web of Science、PubMed、Embase 和 Cochrane Library。本研究的搜索策略和纳入标准共产生了 47 项研究,其中只有 11 项符合荟萃分析的条件。对这些文章的叙述性分析发现,关键肠道微生物群、相关代谢物和炎症因子之间存在相互作用,这些作用调节了 NAFLD 的发生和发展。此外,荟萃分析的结果表明,益生菌补充剂可显著降低 NAFLD 患者的肿瘤坏死因子-α(TNF-α)(标准化均数差(SMD)=-0.52,置信区间(CI):-0.86 至-0.18,p=0.003)和 C 反应蛋白(CRP)(SMD=-0.62,CI:-0.80 至-0.43,p<0.001)。然而,治疗方法是否可以针对 TNF-α和 CRP 来治疗 NAFLD 仍需要进一步研究。因此,这些结果表明,关键肠道微生物群、相关代谢物和炎症因子与 NAFLD 的相互作用可能为 NAFLD 的临床和药物治疗提供新的治疗靶点。